scispace - formally typeset
M

Mark Gerken

Researcher at National Institutes of Health

Publications -  23
Citations -  27894

Mark Gerken is an academic researcher from National Institutes of Health. The author has contributed to research in topics: DNA methylation & Gene. The author has an hindex of 21, co-authored 21 publications receiving 21305 citations. Previous affiliations of Mark Gerken include University of Colorado Denver & Nationwide Children's Hospital.

Papers
More filters
Journal ArticleDOI

Comprehensive molecular portraits of human breast tumours

Daniel C. Koboldt, +355 more
- 04 Oct 2012 - 
TL;DR: The ability to integrate information across platforms provided key insights into previously defined gene expression subtypes and demonstrated the existence of four main breast cancer classes when combining data from five platforms, each of which shows significant molecular heterogeneity.
Journal ArticleDOI

Genomic Classification of Cutaneous Melanoma

Rehan Akbani, +351 more
- 18 Jun 2015 - 
TL;DR: This clinicopathological and multi-dimensional analysis suggests that the prognosis of melanoma patients with regional metastases is influenced by tumor stroma immunobiology, offering insights to further personalize therapeutic decision-making.
Journal ArticleDOI

The Molecular Taxonomy of Primary Prostate Cancer

Adam Abeshouse, +311 more
- 05 Nov 2015 - 
TL;DR: The Cancer Genome Atlas (TCGA) has been used for a comprehensive molecular analysis of primary prostate carcinomas as discussed by the authors, revealing substantial heterogeneity among primary prostate cancers, evident in the spectrum of molecular abnormalities and its variable clinical course.

The Molecular Taxonomy of Primary Prostate Cancer

Adam Abeshouse, +309 more
TL;DR: A comprehensive molecular analysis of 333 primary prostate carcinomas revealed a molecular taxonomy in which 74% of these tumors fell into one of seven subtypes defined by specific gene fusions (ERG, ETV1/4, and FLI1) or mutations (SPOP, FOXA1, and IDH1).
Journal ArticleDOI

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

A. Gordon Robertson, +170 more
- 19 Oct 2017 - 
TL;DR: An analysis of 412 muscle-invasive bladder cancers characterized by multiple TCGA analytical platforms identified 5 expression subtypes that may stratify response to different treatments and identified a poor-survival "neuronal" subtype in which the majority of tumors lacked small cell or neuroendocrine histology.